US20100324289A1 - Chemical Process - Google Patents
Chemical Process Download PDFInfo
- Publication number
- US20100324289A1 US20100324289A1 US12/871,993 US87199310A US2010324289A1 US 20100324289 A1 US20100324289 A1 US 20100324289A1 US 87199310 A US87199310 A US 87199310A US 2010324289 A1 US2010324289 A1 US 2010324289A1
- Authority
- US
- United States
- Prior art keywords
- compound
- formula
- hydrogenation
- catalyst
- platinum
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000001311 chemical methods and process Methods 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract description 44
- 238000000034 method Methods 0.000 claims abstract description 39
- 238000005984 hydrogenation reaction Methods 0.000 claims abstract description 31
- 239000003054 catalyst Substances 0.000 claims abstract description 29
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims abstract description 25
- 239000002904 solvent Substances 0.000 claims abstract description 18
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims abstract description 14
- 229910052723 transition metal Inorganic materials 0.000 claims abstract description 14
- 150000003624 transition metals Chemical class 0.000 claims abstract description 14
- 238000005580 one pot reaction Methods 0.000 claims abstract description 12
- 238000002360 preparation method Methods 0.000 claims abstract description 12
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims abstract description 11
- 239000005864 Sulphur Substances 0.000 claims abstract description 11
- 125000001309 chloro group Chemical group Cl* 0.000 claims abstract description 10
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 claims abstract description 9
- 239000004215 Carbon black (E152) Substances 0.000 claims abstract description 9
- 229930195733 hydrocarbon Natural products 0.000 claims abstract description 9
- 150000002430 hydrocarbons Chemical class 0.000 claims abstract description 9
- 125000005843 halogen group Chemical group 0.000 claims abstract description 6
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims abstract description 5
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims abstract description 5
- 229910052736 halogen Inorganic materials 0.000 claims abstract description 5
- 239000001301 oxygen Substances 0.000 claims abstract description 5
- 229910052760 oxygen Inorganic materials 0.000 claims abstract description 5
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims abstract description 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract description 4
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims description 34
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 24
- 229910052697 platinum Inorganic materials 0.000 claims description 14
- 229910052720 vanadium Inorganic materials 0.000 claims description 9
- 150000002148 esters Chemical class 0.000 claims description 8
- LEONUFNNVUYDNQ-UHFFFAOYSA-N vanadium atom Chemical compound [V] LEONUFNNVUYDNQ-UHFFFAOYSA-N 0.000 claims description 8
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 7
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 6
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 claims description 6
- 229910052799 carbon Inorganic materials 0.000 claims description 6
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 6
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 4
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 claims description 3
- 229910052742 iron Inorganic materials 0.000 claims description 3
- 229910052748 manganese Inorganic materials 0.000 claims description 3
- 239000011572 manganese Substances 0.000 claims description 3
- 229910052763 palladium Inorganic materials 0.000 claims description 3
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 2
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 claims description 2
- 150000002576 ketones Chemical class 0.000 claims description 2
- 238000006243 chemical reaction Methods 0.000 description 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 6
- 0 CC1=NC([Y])=NC(C)=C1N.CC1=NC([Y])=NC(C)=C1[N+](=O)[O-].[2*]/N=N\C1=C(C)N=C([Y])N=C1C.[2*]NNC1=C(C)N=C([Y])N=C1C Chemical compound CC1=NC([Y])=NC(C)=C1N.CC1=NC([Y])=NC(C)=C1[N+](=O)[O-].[2*]/N=N\C1=C(C)N=C([Y])N=C1C.[2*]NNC1=C(C)N=C([Y])N=C1C 0.000 description 6
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 5
- CJOCISIVLSVALH-UHFFFAOYSA-N CC1=NC([Y])=NC(C)=C1N Chemical compound CC1=NC([Y])=NC(C)=C1N CJOCISIVLSVALH-UHFFFAOYSA-N 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
- -1 aromatic nitro compounds Chemical class 0.000 description 4
- 239000001257 hydrogen Substances 0.000 description 4
- 229910052739 hydrogen Inorganic materials 0.000 description 4
- CJJLJBFJNXMANZ-UHFFFAOYSA-N 4,6-dichloro-2-propylsulfanylpyrimidin-5-amine Chemical compound CCCSC1=NC(Cl)=C(N)C(Cl)=N1 CJJLJBFJNXMANZ-UHFFFAOYSA-N 0.000 description 3
- GYDQRQQPRDNLFU-UHFFFAOYSA-N CC1=NC([Y])=NC(C)=C1[N+](=O)[O-] Chemical compound CC1=NC([Y])=NC(C)=C1[N+](=O)[O-] GYDQRQQPRDNLFU-UHFFFAOYSA-N 0.000 description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 229940126062 Compound A Drugs 0.000 description 2
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 2
- 238000013019 agitation Methods 0.000 description 2
- 125000000217 alkyl group Chemical group 0.000 description 2
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 125000001188 haloalkyl group Chemical group 0.000 description 2
- 229960004592 isopropanol Drugs 0.000 description 2
- 239000012299 nitrogen atmosphere Substances 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- 239000008096 xylene Substances 0.000 description 2
- ORMOPLFFXOSAPS-UHFFFAOYSA-N (4,6-dichloro-2-propylsulfanylpyrimidin-5-yl)-(4-methylphenyl)diazene Chemical compound ClC1=NC(SCCC)=NC(Cl)=C1N=NC1=CC=C(C)C=C1 ORMOPLFFXOSAPS-UHFFFAOYSA-N 0.000 description 1
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 description 1
- 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 description 1
- DDEDQHVHVPJFAC-UHFFFAOYSA-N 4,6-dichloro-5-nitro-2-propylsulfanylpyrimidine Chemical compound CCCSC1=NC(Cl)=C([N+]([O-])=O)C(Cl)=N1 DDEDQHVHVPJFAC-UHFFFAOYSA-N 0.000 description 1
- 150000005008 5-aminopyrimidines Chemical class 0.000 description 1
- CATXPADZFUIUAY-RXZAHICESA-N CCCSC1=NC(Cl)=C(/N=N/C2=CC=C(C)C=C2)C(Cl)=N1.CCCSC1=NC(Cl)=C(N)C(Cl)=N1.CCCSC1=NC(Cl)=C(NNC2=CC=C(C)C=C2)C(Cl)=N1 Chemical compound CCCSC1=NC(Cl)=C(/N=N/C2=CC=C(C)C=C2)C(Cl)=N1.CCCSC1=NC(Cl)=C(N)C(Cl)=N1.CCCSC1=NC(Cl)=C(NNC2=CC=C(C)C=C2)C(Cl)=N1 CATXPADZFUIUAY-RXZAHICESA-N 0.000 description 1
- ORMOPLFFXOSAPS-FMQUCBEESA-N ClC1=NC(SCCC)=NC(Cl)=C1\N=N\C1=CC=C(C)C=C1 Chemical compound ClC1=NC(SCCC)=NC(Cl)=C1\N=N\C1=CC=C(C)C=C1 ORMOPLFFXOSAPS-FMQUCBEESA-N 0.000 description 1
- JNCMHMUGTWEVOZ-UHFFFAOYSA-N F[CH]F Chemical compound F[CH]F JNCMHMUGTWEVOZ-UHFFFAOYSA-N 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 238000009903 catalytic hydrogenation reaction Methods 0.000 description 1
- 239000003610 charcoal Substances 0.000 description 1
- 150000004292 cyclic ethers Chemical class 0.000 description 1
- 125000000753 cycloalkyl group Chemical group 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- SMYAIXFOXVRTKH-UHFFFAOYSA-N cyclopentane;2h-triazolo[4,5-d]pyrimidine Chemical class C1CCCC1.N1=CN=CC2=NNN=C21 SMYAIXFOXVRTKH-UHFFFAOYSA-N 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 229960004132 diethyl ether Drugs 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- VUWZPRWSIVNGKG-UHFFFAOYSA-N fluoromethane Chemical compound F[CH2] VUWZPRWSIVNGKG-UHFFFAOYSA-N 0.000 description 1
- 150000002431 hydrogen Chemical class 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 230000010118 platelet activation Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 239000011949 solid catalyst Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
Definitions
- the present invention concerns a process fox the preparation of 5-aminopyrimidines which are useful intermediates in the preparation of pharmaceutically active triazolo[4,5-d]pyrimidine cyclopentanes.
- the present invention provides a process for the preparation of a compound of formula (I):
- X is halogen
- Y is ZR 1
- Z is oxygen or sulphur
- R 1 is C 1-6 alkyl, C 1-6 haloalkyl or C 3-7 cycloalkyl; the process comprising either:
- Alkyl groups and moieties are straight or branched chain and comprise, for example, 1 to 6 (such as 1 to 4) carbon atoms.
- alkyl groups are methyl, ethyl, n-propyl, iso-propyl or tert-butyl.
- Haloalkyl groups and moieties are straight or branched chain and comprise, for example, 1 to 6 (such as 1 to 4) carbon atoms, and 1 to 6 halogen atoms (for example fluorine or chlorine atoms).
- haloalkyl are CH 2 F, CHF 2 , CF 3 , CH 2 CF 3 and 3,3,3-trifluoroprop-1-yl.
- Cycloalkyl is, for example, C 3-6 cycloalkyl, such as cyclopropyl, cyclopentyl or cyclohexyl.
- the present invention provides a process for the preparation of a compound of formula (I):
- Suitable transition metal catalyst for the hydrogenation of a compound of formula (II) is, for example, platinum or palladium, or a combination of platinum with another transition metal such as vanadium, iron or manganese.
- the transition metal catalyst is on a suitable support, for example carbon.
- a suitable solvent for the hydrogenation of a compound of formula (II) is a C 1-6 aliphatic alcohol (such as ethanol and iso-propyl alcohol), an ether (for example a di(C 1-6 alkyl) ether, such as diethylether or methyl tert-butyl ether; or a cyclic ether such as tetrahydrofuran), an ester (for example ethyl acetate) or a hydrocarbon solvent (such as an aromatic hydrocarbon, for example benzene, toluene or a xylene).
- a C 1-6 aliphatic alcohol such as ethanol and iso-propyl alcohol
- an ether for example a di(C 1-6 alkyl) ether, such as diethylether or methyl tert-butyl ether; or a cyclic ether such as tetrahydrofuran
- an ester for example ethyl acetate
- the hydrogenation of a compound of formula (II) is conducted at a temperature in the range 10 to 90° C., for example 20 to 40° C.
- the hydrogenation of a compound of formula (II) is conducted at a pressure of 1 to 10 bar, for example 2 to 4 bar.
- the present invention provides a process for the preparation of a compound of formula (I):
- R 2 is phenyl optionally substituted by chloro, C 1-6 alkyl, C 1-6 alkoxy or (C 1-6 alkyl) 2 N;
- Highly effective mixing for example stirring is used during the one-pot hydrogenation as this aids effective mass transfer during the process.
- Highly effective mixing is used to obtain good contact between the gaseous hydrogen, the solid catalyst and the compound of formula (III) or (IV).
- a suitable catalyst for the one-pot hydrogenation is either a single transition metal or a mixture of two or more transition metals.
- Suitable catalysts are platinum or a mixture of platinum and vanadium. It is usual for the catalyst to be on a suitable support (for example carbon). Examples of these catalysts are platinum on carbon 5-15% w/w; platinum 2-10% w/w (for example 3-7% w/w) and vanadium 0.2-3% w/w on carbon.
- a suitable solvent for the one-pot hydrogenation is a C 1-6 aliphatic alcohol (for example ethanol or iso-propyl alcohol), an ester (for example ethyl acetate), an ether (such as tetrahydrofuran or methyl tert-butyl ether), a hydrocarbon (such as an aromatic hydrocarbon, for example benzene, toluene or a xylene) or a ketone (such as acetone).
- a C 1-6 aliphatic alcohol for example ethanol or iso-propyl alcohol
- an ester for example ethyl acetate
- an ether such as tetrahydrofuran or methyl tert-butyl ether
- a hydrocarbon such as an aromatic hydrocarbon, for example benzene, toluene or a xylene
- ketone such as acetone
- the hydrogenation of a compound of formula (III) or (IV) is conducted at a pressure of 0.5 to 10 bar, for example 2 to 4 bar.
- the present invention provides a process as hereinbefore described wherein X is chloro.
- the present invention provides a process as hereinbefore described wherein Z is sulphur.
- the present invention provides a process as hereinbefore described wherein R 1 is C 1-4 alkyl (such as n-propyl) or C 1-4 haloalkyl (such as 3,3,3-trifluoroprop-1-yl).
- the present invention provides a process as herein described where in 5-15% w/w catalyst is used based on compound of formula (II) or (III).
- This Example illustrates a process for the preparation of 4,6-dichloro-2-(propylthio)pyrimidin-5-amine.
- a Pt/V/C catalyst (available from Degussa; about 3% Pt and 0.6% V adsorbed on charcoal, 30 g) was charged to a vessel and the vessel was purged with nitrogen.
- 4,6-Dichloro-5-nitro-2-(propylthio)pyrimidine (302 g) dissolved in tert-butyl methyl ether (31) was charged to the vessel and agitation was started. The resulting mixture was heated to an initial temperature of 30° C. and then the vessel was pressurised with hydrogen to 3 bar for 3 hours. After the completion of the hydrogenation the catalyst was filtered off. The filtrate was concentrated under reduced pressure to provide the title compound (254 g).
- This Example illustrates a process for the preparation of 4,6-dichloro-2-(propylthio)pyrimidin-5-amine from 4,6-dichloro-5-[(E)-(4-methylphenyl)diazenyl]-2-(propylsulfanyl)pyrimidine
- the Pt/C catalyst (33.3 g, 10% w/w) was added to a reaction vessel that had been purged with nitrogen and maintained under an atmosphere of nitrogen.
- the solution of 4,6-dichloro-5-[(E)-2-(4-methylphenyl)diazenyl]-2-(propylsulfanyl)pyrimidine (150 g, 430.1 mmol) in ethyl acetate (3000 ml ) was added to the reaction vessel containing the catalyst and agitation was initiated.
- the inner temperature was adjusted to 20° C., the nitrogen atmosphere was evacuated, and the vessel was pressurized with 3 bar of hydrogen (hydrogen pressure of 3 bar was maintained throughout the reaction). The temperature was maintained at 20° C.
- reaction solution was cooled to 20° C. and the catalyst filtered off under a nitrogen atmosphere.
- the catalyst was washed with ethyl acetate (300 ml ) and the filtered wash-solution was combined with the filtered reaction solution.
- the ethyl acetate solution was concentrated to 5m1 (ethyl acetate)/g (amine) under vacuum at a maximum temperature of 40° C.
- the resulting solution was extracted twice with aqueous hydrochloric acid (about 3M; 700 ml and 375 ml ) until a pH of 1.5-2 was obtained.
- concentration of the ethyl acetate layer, under vacuum yielded about 93 g of the 4,6-dichloro-2-(propylthio)pyrimidin-5-amine as a yellow oil.
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Hematology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Catalysts (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
The present invention provides a process for the preparation of a compound of formula (I); wherein X is halogen; Y is ZR1; Z is oxygen or sulphur; and R1 is C1-6 alkyl, C1-6 haloalkyl or C3-7 cloalkyl; the process comprising either: hydrogenating a compound of formula (II); with a suitable transition metal catalyst in a C1-6 aliphatic alcohol, an ether, an hydrocarbon as solvent; or, conducting a one-pot hydrogenation of a compound of formula (III): wherein R2 is phenyl optionally substituted by chloro, C1-6 alkyl, C1-6 alkoxy or (C1-6 alkyl)2N; firstly at about 20° C. to form a compound of formula (IV): and then at about 40° C.; both steps (I) and (ii) being carried out in the presence of a suitable catalyst and in the presence of a suitable solvent.
Description
- The present invention concerns a process fox the preparation of 5-aminopyrimidines which are useful intermediates in the preparation of pharmaceutically active triazolo[4,5-d]pyrimidine cyclopentanes.
- The compound [1S-(1α, 2α, 3β (1S*,2R*),5β)]-3-[7-[2-(3,4-difluorophenyl)-cyclopropyl]amino]-5-(propylthio)-3H-1,2,3-triazolo[4,5-d]pyrimidin-3-yl)-5-(2-hydroxyethoxy)-cyclopentane-1,2-diol (Compound A), and similar such compounds, are disclosed in WO 00/34283 and WO 99/05143 as pharmaceutically active P2T (which is now usually referred to as P2Y12) receptor antagonists. Such antagonists can be used as, inter alia, inhibitors of platelet activation, aggregation or degranulation.
- Compounds of formula (I) (see below) are useful in the preparation of Compound A and analogues thereof (see example 3 of WO 01/92263).
- Catalytic hydrogenation of aromatic nitro compounds is disclosed in U.S. Pat. No. 6,09,6924.
- The present invention provides a process for the preparation of a compound of formula (I):
- wherein X is halogen; Y is ZR1; Z is oxygen or sulphur; and R1 is C1-6 alkyl, C1-6 haloalkyl or C3-7 cycloalkyl; the process comprising either:
- a. hydrogenating a compound of formula (II):
- with a suitable transition metal catalyst in a C1-6 aliphatic alcohol, an ether, an ester or a hydrocarbon as solvent;
- or,
- b. conducting a one-pot hydrogenation of a compound of formula (III):
- wherein R2 is phenyl optionally substituted by chloro, C1-6 alkyl, C1-6 alkoxy or (C1-6 alkyl)2N;
- i. firstly at about 20° C. to form a compound of formula (IV):
-
- ii. and then at about 40° C.;
- both steps (i) and (ii) being carried out in the presence of a suitable catalyst and in the presence of a suitable solvent.
- Alkyl groups and moieties are straight or branched chain and comprise, for example, 1 to 6 (such as 1 to 4) carbon atoms. Examples of alkyl groups are methyl, ethyl, n-propyl, iso-propyl or tert-butyl.
- Haloalkyl groups and moieties are straight or branched chain and comprise, for example, 1 to 6 (such as 1 to 4) carbon atoms, and 1 to 6 halogen atoms (for example fluorine or chlorine atoms). Examples of haloalkyl are CH2F, CHF2, CF3, CH2CF3 and 3,3,3-trifluoroprop-1-yl.
- Cycloalkyl is, for example, C3-6 cycloalkyl, such as cyclopropyl, cyclopentyl or cyclohexyl.
- In one particular aspect the present invention provides a process for the preparation of a compound of formula (I):
- wherein X is halogen; Y is ZR1; Z is oxygen or sulphur; and R1 is C1-6 alkyl, C1-6 haloalkyl or C3-7 cycloalkyl; the process comprising hydrogenating a compound of formula (II):
- with a suitable transition metal catalyst in C1-6 aliphatic alcohol, an ether, an ester or a hydrocarbon as solvent.
- Suitable transition metal catalyst for the hydrogenation of a compound of formula (II) is, for example, platinum or palladium, or a combination of platinum with another transition metal such as vanadium, iron or manganese. In a further aspect of the invention the transition metal catalyst is on a suitable support, for example carbon.
- A suitable solvent for the hydrogenation of a compound of formula (II) is a C1-6 aliphatic alcohol (such as ethanol and iso-propyl alcohol), an ether (for example a di(C1-6 alkyl) ether, such as diethylether or methyl tert-butyl ether; or a cyclic ether such as tetrahydrofuran), an ester (for example ethyl acetate) or a hydrocarbon solvent (such as an aromatic hydrocarbon, for example benzene, toluene or a xylene).
- In another aspect the hydrogenation of a compound of formula (II) is conducted at a temperature in the range 10 to 90° C., for example 20 to 40° C.
- In yet another aspect the hydrogenation of a compound of formula (II) is conducted at a pressure of 1 to 10 bar, for example 2 to 4 bar.
- In a further aspect the present invention provides a process for the preparation of a compound of formula (I):
- wherein X is halogen; Y is ZR1; Z is oxygen or sulphur; and R1 is C1-6 alkyl, C1-6 haloalkyl or C3-7 cycloalkyl; the process comprising conducting a one-pot hydrogenation of a compound of formula (III):
- wherein R2 is phenyl optionally substituted by chloro, C1-6 alkyl, C1-6 alkoxy or (C1-6 alkyl)2N;
- i. firstly at 10 to 25° C. to form a compound of formula (IV):
- ii. and then hydrogenating at about 35 to 50° C.;
- both steps (i) and (ii) being carried out in the presence of a suitable catalyst and in the presence of a suitable solvent.
- Highly effective mixing (for example stirring) is used during the one-pot hydrogenation as this aids effective mass transfer during the process. Highly effective mixing is used to obtain good contact between the gaseous hydrogen, the solid catalyst and the compound of formula (III) or (IV).
- A suitable catalyst for the one-pot hydrogenation is either a single transition metal or a mixture of two or more transition metals. Suitable catalysts are platinum or a mixture of platinum and vanadium. It is usual for the catalyst to be on a suitable support (for example carbon). Examples of these catalysts are platinum on carbon 5-15% w/w; platinum 2-10% w/w (for example 3-7% w/w) and vanadium 0.2-3% w/w on carbon.
- A suitable solvent for the one-pot hydrogenation is a C1-6 aliphatic alcohol (for example ethanol or iso-propyl alcohol), an ester (for example ethyl acetate), an ether (such as tetrahydrofuran or methyl tert-butyl ether), a hydrocarbon (such as an aromatic hydrocarbon, for example benzene, toluene or a xylene) or a ketone (such as acetone).
- In yet another aspect the hydrogenation of a compound of formula (III) or (IV) is conducted at a pressure of 0.5 to 10 bar, for example 2 to 4 bar.
- In a still further aspect the present invention provides a process as hereinbefore described wherein X is chloro.
- In another aspect the present invention provides a process as hereinbefore described wherein Z is sulphur.
- In yet another aspect the present invention provides a process as hereinbefore described wherein R1 is C1-4 alkyl (such as n-propyl) or C1-4 haloalkyl (such as 3,3,3-trifluoroprop-1-yl).
- In yet another aspect the present invention provides a process as herein described where in 5-15% w/w catalyst is used based on compound of formula (II) or (III).
- The following Examples illustrate the invention.
- This Example illustrates a process for the preparation of 4,6-dichloro-2-(propylthio)pyrimidin-5-amine.
- A Pt/V/C catalyst (available from Degussa; about 3% Pt and 0.6% V adsorbed on charcoal, 30 g) was charged to a vessel and the vessel was purged with nitrogen. 4,6-Dichloro-5-nitro-2-(propylthio)pyrimidine (302 g) dissolved in tert-butyl methyl ether (31) was charged to the vessel and agitation was started. The resulting mixture was heated to an initial temperature of 30° C. and then the vessel was pressurised with hydrogen to 3 bar for 3 hours. After the completion of the hydrogenation the catalyst was filtered off. The filtrate was concentrated under reduced pressure to provide the title compound (254 g).
- This Example illustrates a process for the preparation of 4,6-dichloro-2-(propylthio)pyrimidin-5-amine from 4,6-dichloro-5-[(E)-(4-methylphenyl)diazenyl]-2-(propylsulfanyl)pyrimidine
- The Pt/C catalyst (33.3 g, 10% w/w) was added to a reaction vessel that had been purged with nitrogen and maintained under an atmosphere of nitrogen. The solution of 4,6-dichloro-5-[(E)-2-(4-methylphenyl)diazenyl]-2-(propylsulfanyl)pyrimidine (150 g, 430.1 mmol) in ethyl acetate (3000 ml ) was added to the reaction vessel containing the catalyst and agitation was initiated. The inner temperature was adjusted to 20° C., the nitrogen atmosphere was evacuated, and the vessel was pressurized with 3 bar of hydrogen (hydrogen pressure of 3 bar was maintained throughout the reaction). The temperature was maintained at 20° C. for about 30 minutes and then it was increased to 40° C. and maintained for 150 minutes. When the reaction was complete (full conversion) the reaction solution was cooled to 20° C. and the catalyst filtered off under a nitrogen atmosphere. The catalyst was washed with ethyl acetate (300 ml ) and the filtered wash-solution was combined with the filtered reaction solution. The ethyl acetate solution was concentrated to 5m1 (ethyl acetate)/g (amine) under vacuum at a maximum temperature of 40° C. The resulting solution was extracted twice with aqueous hydrochloric acid (about 3M; 700 ml and 375 ml ) until a pH of 1.5-2 was obtained. The concentration of the ethyl acetate layer, under vacuum, yielded about 93 g of the 4,6-dichloro-2-(propylthio)pyrimidin-5-amine as a yellow oil.
Claims (20)
1. A process for the preparation of a compound of formula (I):
wherein
X is halogen;
Y is ZR1;
Z is oxygen or sulphur; and
R1 is C1-6 alkyl, C1-6 haloalkyl or C3-7 cycloalkyl;
the process comprising either:
hydrogenating a compound of formula (II):
with a suitable transition metal catalyst in a C1-6 aliphatic alcohol, an ether, an ester or a hydrocarbon as solvent; or,
conducting a one-pot hydrogenation of a compound of formula (III):
wherein R2 is phenyl optionally substituted by chloro, C1-6 alkyl, C1-6 alkoxy or (C1-6 alkyl)2N;
(i) firstly at about 20° C. to form a compound of formula (IV):
2. A process as claimed in claim 1 wherein X is chloro.
3. A process as claimed in claim 1 wherein Z is sulphur.
4. A process as claimed in claim 1 , wherein R1 is C1-4 alkyl or C1-4 haloalkyl.
5. A process as claimed in claim 1 , wherein Y is ZR1; Z is sulphur; and R1 is n-propyl.
6. A process as claimed in claim 1 wherein the transition metal catalyst for the hydrogenation of a compound of formula (II) is selected from platinum, palladium and a combination of platinum with a transition metal selected from vanadium, iron and manganese.
7. A process as claimed claim 6 wherein the transition metal catalyst is on a carbon support.
8. A process as claimed in claim 1 wherein the solvent for the hydrogenation of a compound of formula (II) is a C1-6 aliphatic alcohol, an ether, an ester or a hydrocarbon solvent.
9. A process as claimed in claim 1 wherein the hydrogenation of a compound of formula (II) is conducted at a temperature in the range 10 to 90° C.
10. A process as claimed in claim 9 wherein the hydrogenation of a compound of formula (II) is conducted at a temperature in the range 20 to 40° C.
11. A process as claimed in claim 1 wherein the hydrogenation of a compound of formula (II) is conducted at a pressure of 1 to 10 bar.
12. A process as claimed in claim 10 wherein the hydrogenation of a compound of formula (II) is conducted at a pressure of 2 to 4 bar.
13. A process as claimed in claim 1 for the preparation of a compound of formula (I) in which X is chloro, Y is ZR1; Z is sulphur; and R1 is n-propyl; the process comprising hydrogenating a compound of formula (II) in solvent comprising an ether at a pressure of 2 to 4 bar, a temperature in the range 20 to 40° C. and a Pt/V/C catalyst.
14. A process as claimed in claim 1 wherein the catalyst for the one-pot hydrogenation is selected from platinum and a mixture of platinum and vanadium.
15. A process as claimed in claim 13 wherein the catalyst for the one-pot hydrogenation is selected from platinum on carbon 5-15% w/w; platinum 2-10% w/w and vanadium 0.2-3% w/w on carbon.
16. A process as claimed in claim 12 , wherein the solvent for the one-pot hydrogenation is selected from a C1-6 aliphatic alcohol, an ester, an ether, a hydrocarbon and a ketone.
17. A process as claimed in claim 13 , wherein the hydrogenation of a compound of formula (III) or (IV) is conducted at a pressure of 2 to 4 bar.
18. A process as claimed in claim 1 for the preparation of a compound of formula (I) in which X is chloro, Y is ZR1; Z is sulphur; and R1 is n-propyl; the process comprising a one-pot hydrogenation of a compound of formula (III) wherein the hydrogenation is conducted in a solvent of ethyl acetate at a pressure of 2 to 4 bar and using a Pt/C catalyst.
19. A process as claimed in claim 1 wherein:
X is chloro;
Z is sulphur;
R1 is n-propyl;
the transition metal catalyst for the hydrogenation of a compound of formula (II) is selected from platinum, palladium and a combination of platinum with a transition metal selected from vanadium, iron and manganese; and
the solvent for the hydrogenation of a compound of formula (II) is a C1-6 aliphatic alcohol, an ether, an ester or a hydrocarbon solvent;
20. A process as claimed in claim 19 wherein:
the hydrogenation of the compound of formula (II) is conducted at a temperature in the range 20 to 40° C.;
the hydrogenation of the compound of formula (II) is conducted at a pressure of 2 to 4 bar;
the catalyst for the one-pot hydrogenation is selected from platinum on carbon 5-15% w/w, platinum 2-10% w/w and vanadium 0.2-3% w/w on carbon; and
the hydrogenation of the compound of formula (III) or (IV) is conducted at a pressure of 2 to 4 bar.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US12/871,993 US20100324289A1 (en) | 2004-03-31 | 2010-08-31 | Chemical Process |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE0401001A SE0401001D0 (en) | 2004-03-31 | 2004-03-31 | Chemical process |
| SE0401001-3 | 2004-03-31 | ||
| PCT/GB2005/001188 WO2005095358A2 (en) | 2004-03-31 | 2005-03-29 | Process for the preparation of aminopyrimidines |
| US10/599,377 US7799914B2 (en) | 2004-03-31 | 2005-03-29 | Chemical process |
| US12/871,993 US20100324289A1 (en) | 2004-03-31 | 2010-08-31 | Chemical Process |
Related Parent Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/GB2005/001188 Continuation WO2005095358A2 (en) | 2004-03-31 | 2005-03-29 | Process for the preparation of aminopyrimidines |
| US11/599,377 Continuation US7243186B2 (en) | 2003-12-22 | 2006-11-15 | Method of optimizing performance of flash memory |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| US20100324289A1 true US20100324289A1 (en) | 2010-12-23 |
Family
ID=32294337
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US10/599,377 Expired - Fee Related US7799914B2 (en) | 2004-03-31 | 2005-03-29 | Chemical process |
| US12/871,993 Abandoned US20100324289A1 (en) | 2004-03-31 | 2010-08-31 | Chemical Process |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US10/599,377 Expired - Fee Related US7799914B2 (en) | 2004-03-31 | 2005-03-29 | Chemical process |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US7799914B2 (en) |
| EP (2) | EP1751117B1 (en) |
| JP (1) | JP5059599B2 (en) |
| KR (1) | KR101164265B1 (en) |
| CN (2) | CN101851212A (en) |
| AT (1) | ATE517096T1 (en) |
| AU (1) | AU2005227727B2 (en) |
| BR (1) | BRPI0509323A (en) |
| CA (1) | CA2560094C (en) |
| CY (1) | CY1111847T1 (en) |
| DK (1) | DK1751117T3 (en) |
| ES (1) | ES2368069T3 (en) |
| HR (1) | HRP20110658T1 (en) |
| IL (1) | IL177998A (en) |
| NO (1) | NO20064117L (en) |
| NZ (2) | NZ550128A (en) |
| PL (1) | PL1751117T3 (en) |
| PT (1) | PT1751117E (en) |
| SE (1) | SE0401001D0 (en) |
| SG (1) | SG151311A1 (en) |
| SI (1) | SI1751117T1 (en) |
| WO (1) | WO2005095358A2 (en) |
| ZA (1) | ZA200607708B (en) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE0401001D0 (en) * | 2004-03-31 | 2004-03-31 | Astrazeneca Ab | Chemical process |
| CA2636619A1 (en) * | 2006-02-13 | 2007-08-23 | Lonza Ag | Reduction of 5-(aryl-diazenyl)-4,6-dihalo-pyrimidine |
| ES2558843T3 (en) | 2008-09-09 | 2016-02-09 | Astrazeneca Ab | Procedure for preparing [1S- [1-alpha, 2-alpha, 3-beta (1S *, 2R *), 5-beta]] - 3- [7- [2- (3,4-difluorophenyl) -cyclopropylamino] -5- (propylthio) -3H-1,2,3-triazolo [4,5-d] pyrimidin-3-yl] -5- (2-hydroxyethoxy) cyclopentane-1,2-diol and its intermediates |
| EP2305376A1 (en) * | 2009-09-23 | 2011-04-06 | Lonza Ltd. | Process and catalyst for the catalytic hydrogenation of aromatic and heteroaromatic nitro compounds |
| EP2834247A4 (en) | 2012-04-05 | 2016-03-30 | Reddys Lab Ltd Dr | Preparation of ticagrelor |
| CN103130726A (en) * | 2013-02-07 | 2013-06-05 | 许学农 | Preparation method of Ticagrelor intermediate 4,6-dichloro-2-(pyridinecarboxylic)-5- aminopyrimidine |
| WO2014206187A1 (en) | 2013-06-24 | 2014-12-31 | 苏州明锐医药科技有限公司 | Preparation method of ticagrelor and intermediates thereof |
| US10329288B2 (en) | 2013-08-22 | 2019-06-25 | Genentech, Inc. | Process for preparing a compound |
| CN103588712B (en) * | 2013-11-08 | 2016-06-08 | 南京欧信医药技术有限公司 | A kind of pyrimidines and preparation method thereof and application |
| CN103923020A (en) * | 2014-04-02 | 2014-07-16 | 黄河三角洲京博化工研究院有限公司 | Preparation method of 2-propylthio-4,6-dichloro-5-aminopyrimidine |
| CN105020602B (en) * | 2014-04-30 | 2017-12-08 | 欧普照明股份有限公司 | A kind of LED |
| CN103992277A (en) * | 2014-05-16 | 2014-08-20 | 苏州天马精细化学品股份有限公司 | Method for preparing intermediate 4,6-dichloro-5-amino-2-propylthiouracil of ticagrelor |
| CN105294573B (en) * | 2015-06-16 | 2018-07-10 | 厦门医学院 | A kind of method for synthesizing 4,6- bis- chloro- 2- (rosickyite base) -5- aminopyrimidines |
| CN116283796A (en) * | 2023-02-14 | 2023-06-23 | 上海汇伦医药股份有限公司 | A kind of method of circular catalytic hydrogenation nitro compound |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6096924A (en) * | 1995-05-19 | 2000-08-01 | Novartis Ag | Process for the catalytic hydrogeneration of aromatic nitro compounds |
| US6818720B2 (en) * | 2001-11-08 | 2004-11-16 | Degussa Ag | Supported hydrogenating catalyst in powder form |
| US7067663B2 (en) * | 2000-06-02 | 2006-06-27 | Astrazeneca Ab | Triazolo pyrimidine compounds |
| US7799914B2 (en) * | 2004-03-31 | 2010-09-21 | Astrazeneca Ab | Chemical process |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUT64967A (en) * | 1991-04-06 | 1994-03-28 | Fisons Plc | Atp analogues and pharmaceutical compositions containing them |
| TW530058B (en) | 1997-07-22 | 2003-05-01 | Astra Pharma Prod | Triazolo [4,5-d]pyrimidine compounos and their use and process for preparation |
| TWI229674B (en) | 1998-12-04 | 2005-03-21 | Astra Pharma Prod | Novel triazolo[4,5-d]pyrimidine compounds, pharmaceutical composition containing the same, their process for preparation and uses |
-
2004
- 2004-03-31 SE SE0401001A patent/SE0401001D0/en unknown
-
2005
- 2005-03-29 NZ NZ550128A patent/NZ550128A/en not_active IP Right Cessation
- 2005-03-29 PT PT05729737T patent/PT1751117E/en unknown
- 2005-03-29 CA CA2560094A patent/CA2560094C/en not_active Expired - Fee Related
- 2005-03-29 BR BRPI0509323-6A patent/BRPI0509323A/en not_active Application Discontinuation
- 2005-03-29 JP JP2007505626A patent/JP5059599B2/en not_active Expired - Fee Related
- 2005-03-29 KR KR1020067021443A patent/KR101164265B1/en not_active Expired - Fee Related
- 2005-03-29 AU AU2005227727A patent/AU2005227727B2/en not_active Ceased
- 2005-03-29 EP EP05729737A patent/EP1751117B1/en not_active Expired - Lifetime
- 2005-03-29 CN CN201010206146A patent/CN101851212A/en active Pending
- 2005-03-29 AT AT05729737T patent/ATE517096T1/en active
- 2005-03-29 SI SI200531366T patent/SI1751117T1/en unknown
- 2005-03-29 PL PL05729737T patent/PL1751117T3/en unknown
- 2005-03-29 US US10/599,377 patent/US7799914B2/en not_active Expired - Fee Related
- 2005-03-29 WO PCT/GB2005/001188 patent/WO2005095358A2/en not_active Ceased
- 2005-03-29 ES ES05729737T patent/ES2368069T3/en not_active Expired - Lifetime
- 2005-03-29 SG SG200902108-0A patent/SG151311A1/en unknown
- 2005-03-29 CN CN2005800102841A patent/CN1938284B/en not_active Expired - Lifetime
- 2005-03-29 NZ NZ587999A patent/NZ587999A/en not_active IP Right Cessation
- 2005-03-29 DK DK05729737.6T patent/DK1751117T3/en active
- 2005-03-29 EP EP10179703A patent/EP2308853A1/en not_active Withdrawn
- 2005-03-29 HR HR20110658T patent/HRP20110658T1/en unknown
-
2006
- 2006-09-11 IL IL177998A patent/IL177998A/en not_active IP Right Cessation
- 2006-09-13 NO NO20064117A patent/NO20064117L/en not_active Application Discontinuation
- 2006-09-14 ZA ZA200607708A patent/ZA200607708B/en unknown
-
2010
- 2010-08-31 US US12/871,993 patent/US20100324289A1/en not_active Abandoned
-
2011
- 2011-09-15 CY CY20111100890T patent/CY1111847T1/en unknown
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6096924A (en) * | 1995-05-19 | 2000-08-01 | Novartis Ag | Process for the catalytic hydrogeneration of aromatic nitro compounds |
| US7067663B2 (en) * | 2000-06-02 | 2006-06-27 | Astrazeneca Ab | Triazolo pyrimidine compounds |
| US6818720B2 (en) * | 2001-11-08 | 2004-11-16 | Degussa Ag | Supported hydrogenating catalyst in powder form |
| US7799914B2 (en) * | 2004-03-31 | 2010-09-21 | Astrazeneca Ab | Chemical process |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20100324289A1 (en) | Chemical Process | |
| US7759486B2 (en) | 2,4,5-Trisubstituted pyrimidine compounds | |
| PL198640B1 (en) | PYRROLO[2,3-d]PYRIMIDINE COMPOUNDS | |
| US20050288503A1 (en) | Novel compounds | |
| US12187714B2 (en) | Process for preparing aminopyrimidine derivatives | |
| US8242044B2 (en) | Process and catalyst | |
| HK1156029A (en) | Process for the preparation of aminopyrimidines | |
| CZ20031021A3 (en) | Process for preparing substituted aniline derivatives | |
| HK1103727B (en) | Process for the preparation of aminopyrimidines | |
| MXPA06011235A (en) | Chemical process | |
| JP5078607B2 (en) | Chemical process | |
| HK1172580B (en) | A process and catalyst for the catalytic hydrogenation of aromatic and heteroaromatic nitro compounds | |
| MXPA06011231A (en) | Chemical process |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AS | Assignment |
Owner name: ASTRAZENECA AB, SWEDEN Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:LARSSON, ULF;RADEVIK, KAJSA;REEL/FRAME:024948/0620 Effective date: 20060825 |
|
| STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |